When looking to the BOM and BUP trials being completed this year, it could signal an initial partnership with benchmarks that can be increased as they initiate B p3 and beyond. This package is very compelling.
P seems to be 2 H of 2017 unless someone pulls the trigger after the mid term reports which is very possible. The longer one waits, the more expensive it will be to win the contest. This should finance all 5 trials.
K ovarian 2a in 2h is incredible. That's fast in cancer trial time.
This is the year of partnerships. One might want to consider where they are when the announcements begin. The mms can play for now. Will they catch the rocket ship in time? Hope not.